CAC
TEVA icon

Cowen and Company’s Teva Pharmaceuticals TEVA Stock Holding History

Cowen and Company’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-100,000
Closed -$2.5K – 678
2022
Q4 		$2.5K Buy
+100,000
New +$873K ﹤0.01% 550
2020
Q2 		– Sell
-1,426,300
Closed -$3.38M – 476
2020
Q1 		$3.38M Buy
+1,426,300
New +$14.6M 0.78% 26

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Cowen and Company's TEVA Position: Q1 2023 in Review

Cowen and Company sold out of Teva Pharmaceuticals (TEVA) in Q1 2023, closing a stake of 176,942 shares — an estimated $1.61M sold.

Cowen and Company first reported a position in TEVA in Q4 2021 and held it in 5 quarters. The position peaked at $1.61M in Q4 2022. 438 funds tracked by Wall St. Rank hold TEVA as of Q1 2023.

  • Cowen and Company reported no remaining Teva Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Cowen and Company sold 176,942 Teva Pharmaceuticals shares in Q1 2023, an estimated $1.61M.
  • Cowen and Company first reported a position in Teva Pharmaceuticals in Q4 2021 and held it in 5 quarters.
  • Cowen and Company's Teva Pharmaceuticals position peaked at $1.61M in Q4 2022.
  • 438 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2023.

Based on Cowen and Company's 13F filing for Q1 2023, filed 9 May 2023.